ABSTRACT OBJECTIVES This study is the first report of 2 cases of HighLife (HighLife, Paris, France) implantation in humans.
T ranscatheter mitral valve implantation (TMVI) represents a promising approach to treating mitral regurgitation (MR) in patients at increased risk of perioperative mortality (1) . To date, several transcatheter mitral valve systems are under preclinical and clinical investigation (1) (2) (3) (4) (5) . Each of them carries specific features that have the goal to ensure a predictable delivery and This device has already been tested in acute and chronic animals with promising outcomes (data not published). No human cases have been described in the published data. The present study is the first report of 2 cases of HighLife implantation in humans.
TMVI DEVICE OVERVIEW
The HighLife TMVI technology has been described previously ( Figure 1 ) (6) . Briefly, the device, which is currently available only in 1 size, is composed of 2 separate components. The valve consists of a nitinol alloy-based, self-expanding frame, covered with a polyester graft and trileaflet bovine pericardium. The frame shape has a pre-formed groove in the annular region so as to create an interference with the loosely placed SAI. The SAI is a polymer tube, covered with a polyester graft with a nitinol hook that allows for the creation of a ring with a single definite length 
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Transcatheter Mitral Valve Implantation coronary artery bypass grafting who developed severe ischemic cardiomyopathy and functional MR.
He has had multiple previous in-hospital admissions for heart failure despite optimal medical therapy. Images of transcatheter mitral valve prosthesis and subannular implant.
FIGURE 2 Mitral Annulus
The mitral annulus was tracked by manually placing several segmentation points for cubic spline interpolation along the insertion of the posterior mitral leaflet and along the contour of the anterior peak comprising the fibrous intervalvular continuity.
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FIGURE 3 LVOT Patency Assessment by Multislice Computed Tomography
Multislice computed tomography images of LVOT patency assessment. 3-D ¼ 3-dimensional; LVOT ¼ left ventricle outflow tract.
RESULTS
Both procedures were performed in the catheteriza- Barbanti et al.
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with the SAI by manually pushing the device toward the atrium, and the SAI is further pushed until it was pressed against the subannular groove. Then the inflow end of the transcatheter mitral valve is deployed from the delivery catheter ( Figure 6 ). The catheter is closed and removed from the patient's heart and the access to the apex was closed. The guidewire loop was removed from the SAI and the SDC by pulling on 1 end.
Procedural times of both cases were around 4 hours ( Table 2) . Both patients remained hemodynamically stable during the whole procedures Barbanti et al. Barbanti et al.
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